title: New adipocytokines (vaspin, apelin, visfatin, adiponectin) levels in children treated with valproic acid.
abstract: OBJECTIVE
  To investigate the relationship between the newly discovered adipocytokines and increasing body weight (paralleled by increased insulin resistance), and antiepileptic drug therapy with valproic acid (VPA).
  
  
  METHODS
  44 children with idiopathic, generalized epilepsy treated with valproic acid (VPA), and 40 control group children were included in this study.
  
  
  RESULTS
  Both the VPA-treated group and the control group showed no significant difference in terms of age, total cholesterol and LDL-cholesterol. Subjects in the VPA group had significantly higher BMI-SDS than control subjects (2.3±0.15 vs -0.04±0.8, p<0.001). HOMA-IR, apelin and visfatin levels were significantly increased (4.95±2.07 vs 1.46 vs 0.6, p<0.001; 2.21±1.14 vs 0.57±0.15, p<0.001; 31±12 vs 18.4±10.4, p<0.001; respectively), and adiponectin levels were significantly lower in the VPA group (2.02±1.03 vs 12.4±6.1, p<0.001). Triglyceride levels were significantly increased (126±70 vs 80±40 mg/dL, p=0.001), and HDL-cholesterol levels were significantly lower in the VPA group. Vaspin levels were higher in the VPA group than the control group, but the difference was not significant.
  
  
  CONCLUSIONS
  Based on the findings of this study, apelin, visfatin and adiponectin levels may be considered as potential regulators of glucose and fat metabolism during valproic acid therapy.
authors.affiliation: Department of Pediatrics, GATA Medical Faculty, Istanbul.
authors.forename: Cihan
authors.initials: C
authors.lastname: Meral
authors.forename: Ferhat
authors.initials: F
authors.lastname: Cekmez
authors.forename: Sebahattin
authors.initials: S
authors.lastname: Vurucu
authors.forename: Emre
authors.initials: E
authors.lastname: Tascılar
authors.forename: Ozgur
authors.initials: O
authors.lastname: Pirgon
authors.forename: F Emre
authors.initials: FE
authors.lastname: Canpolat
authors.forename: Osman Metin
authors.initials: OM
authors.lastname: Ipcioglu
authors.forename: Gokhan
authors.initials: G
authors.lastname: Aydemir
authors.forename: Secil
authors.initials: S
authors.lastname: Aydınoz
mesh_terms: D054392:Adipokines / Q000097:blood*; D052242:Adiponectin / Q000097:blood*; D000293:Adolescent; D000927:Anticonvulsants / Q000009:adverse effects* / Q000627:therapeutic use; D000073861:Apelin; D002648:Child; D005260:Female; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000097:blood*; D008297:Male; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood*; D015843:Serpins / Q000097:blood*; D014635:Valproic Acid / Q000009:adverse effects* / Q000627:therapeutic use; D015430:Weight Gain / Q000187:drug effects
chemical_list: C115436:APLN protein, human; D054392:Adipokines; D052242:Adiponectin; D000927:Anticonvulsants; D000073861:Apelin; D036341:Intercellular Signaling Peptides and Proteins; C507339:SERPINA12 protein, human; D015843:Serpins; D014635:Valproic Acid; D054409:Nicotinamide Phosphoribosyltransferase